Medpace Inc. (MEDP)
Bid | 292.13 |
Market Cap | 9.84B |
Revenue (ttm) | 2.08B |
Net Income (ttm) | 398.09M |
EPS (ttm) | 12.64 |
PE Ratio (ttm) | 25.56 |
Forward PE | 26.72 |
Analyst | Hold |
Ask | 355.35 |
Volume | 311,999 |
Avg. Volume (20D) | 309,024 |
Open | 325.85 |
Previous Close | 326.34 |
Day's Range | 322.08 - 325.80 |
52-Week Range | 302.01 - 459.77 |
Beta | 1.47 |
About MEDP
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory...
Analyst Forecast
According to 9 analyst ratings, the average rating for MEDP stock is "Hold." The 12-month stock price forecast is $367, which is an increase of 13.59% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription

1 month ago · businesswire.com
Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2024 ResultsCINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Finan...